Abstract:Natural killer (NK) cell-based immunotherapy represents a promising strategy to overcome the bottlenecks of cancer treatment. However, the therapeutic efficacy is greatly limited by downregulation of recognition ligands on the tumor cell surface, and the immunosuppressive effects can be thwarted by the tumor microenvironment such as secretion of transforming growth factor-beta (TGF-β), which could stunt the NK cell-mediated immune response. To overcome these limitations, herein we developed a nanoemulsion system (SSB NMs) to co-deliver TGF-β inhibitor and selenocysteine (SeC) to achieve amplified anticancer efficacy. SSB NMs significantly enhanced the lytic potency of NK92 cells by 2.1-fold. Moreover, a subtoxic dose of SSB NMs effectively sensitized MDA-MB-231 triple-negative breast cancer (TNBC) cells to NK cells derived from seven clinical patients, resulting in an up to 13.8-fold increase in cancer lysis. Mechanistic studies reveal that the sensitizing effects relied on natural killer group 2, member D (NKG2D)/NKG2D ligands (NKG2DLs) signaling with the involvement of DNA damage response. SSB NMs also effectively restrained TGF-β/TGF-β RI/Smad2/3 signaling, which thus enhanced NKG2DL expression on tumor cells and stimulated NKG2D surface expression on NK92 cells, ultimately contributing to the enhanced immune response. Furthermore, SSB NMs sustained release of SeC and TGF-β inhibitor and synergized with NK92 cells to induce significant anticancer effects <i>in vivo</i>. Together, this study not only demonstrates a simple strategy for the design of a nanoemulsion to co-deliver synergistic drugs but also sheds light on the application and action mechanisms in NK cell adaptive therapy against breast cancer, especially TNBCs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.9b10103?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.9b10103</a>.Figures of the immunosensitizing effects of NK92 cells induced by SSB NMs against MDA-MB-231 cancer cells; cytolytic activities of NK92 cells after preincubated with SeC against cancer cells; SSB NMs augment the cytolytic activities of NK92 cells on HCC1937 and MDA-MB-468 cells; SSB NMs augment the cytolytic activities of NK92 cells by determining LDH release; characterization of NK cells from patients; cellular uptake and intracellular localization of Cou6-labeled and SSB NMs in MDA-MB-231 cells; expression of DR4/5, TRAIL, and FasL; comet assay and immunocytochemistry detecting DNA damage; cell cycle analysis by flow cytometry; antimigration effects of SeC and SSB NMs; tumor images and tumor inhibition ratio; hematological analysis; H&E-stained images of major organs; H&E-stained images and clinical chemistry evaluation in orthotopic tumor model (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.9b10103/suppl_file/nn9b10103_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Selenium‐Containing Nanoparticles Combine the NK Cells Mediated Immunotherapy with Radiotherapy and Chemotherapy

A Powerful Antitumor “trident”: the Combination of Radio-, Immuno- and Anti-Angiogenesis Therapy Based on Mesoporous Silica Single Coated Gold Nanoparticles

Selenium-containing Nanoparticles Synergistically Enhance Pemetrexed&NK Cell-Based Chemoimmunotherapy.

A Nanotherapeutic Strategy to Reverse NK Cell Exhaustion

Selenopeptide Nanomedicine Activates Natural Killer Cells for Enhanced Tumor Chemoimmunotherapy

Selenium nanoparticles regulates selenoprotein to boost cytokine-induced killer cells-based cancer immunotherapy

Highly active selenium nanotherapeutics combined with metformin to achieve synergistic sensitizing effect on NK cells for osteosarcoma therapy

Immunomodulatory roles of selenium nanoparticles: Novel arts for potential immunotherapy strategy development

Combined use of NK cells and radiotherapy in the treatment of solid tumors

Selenium-driven enhancement of synergistic cancer chemo-/radiotherapy by targeting nanotherapeutics

Selenium‐Containing Nanocomplexes Achieve Dual Immune Checkpoint Blockade for NK Cell Reinvigoration

Boosting Natural Killer Cell-Based Cancer Immunotherapy with Selenocystine/Transforming Growth Factor-Beta Inhibitor-Encapsulated Nanoemulsion

Dual Synergistic Tumor‐Specific Polymeric Nanoparticles for Efficient Chemo‐Immunotherapy

Cooperative Self-Assembled Nanoparticle Induces Sequential Immunogenic Cell Death and Toll-Like Receptor Activation for Synergistic Chemo-immunotherapy

Radiotherapy-induced enrichment of EGF-modified doxorubicin nanoparticles enhances the therapeutic outcome of lung cancer

Selenium nanoparticles enhance the anti-tumor immune responses of anti-4-1BB antibody and alleviate the adverse effects on mice

Combination Nanodrug Delivery Systems Facilitate the Syncretism of Chemotherapy with Immunotherapy to Promote Cancer Treatment

Coordination and Redox Dual‐Responsive Mesoporous Organosilica Nanoparticles Amplify Immunogenic Cell Death for Cancer Chemoimmunotherapy

Poly(Vinylpyrollidone)‐ and Selenocysteine‐Modified Bi2Se3 Nanoparticles Enhance Radiotherapy Efficacy in Tumors and Promote Radioprotection in Normal Tissues

Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy

Targeted Heating of Mitochondria Greatly Augments Nanoparticle-Mediated Cancer Chemotherapy